US Foreign Aid Freeze Cripples HIV Prevention in Lesotho, Triggers Global Job Losses
In Lesotho, the suspension of US foreign aid has halted HIV prevention programs, impacting hundreds of children and jeopardizing access to vital medication, resulting in widespread job losses within the USAID sector and causing uncertainty among international development professionals.
US Foreign Aid Freeze Cripples HIV Prevention in Lesotho, Triggers Global Job Losses
In Lesotho, the suspension of US foreign aid has halted HIV prevention programs, impacting hundreds of children and jeopardizing access to vital medication, resulting in widespread job losses within the USAID sector and causing uncertainty among international development professionals.
Progress
36% Bias Score
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Progress
32% Bias Score
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Progress
40% Bias Score
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Progress
44% Bias Score
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Progress
52% Bias Score
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Progress
48% Bias Score